<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>20/20 GENE SYSTEMS, INC.</title>
	<atom:link href="http://www.2020gene.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.2020gene.com</link>
	<description>utilizes novel technologies in the development of innovative, proprietary diagnostics for biodefense, cancer and autoimmune diseases.</description>
	<lastBuildDate>Sun, 25 Mar 2012 21:24:37 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>October 8, 2010  20/20 GeneSystems Awarded $3 million from National Cancer Institute to Develop Personalized Medicine Tests</title>
		<link>http://www.2020gene.com/october-8-2010-2020-genesystems-awarded-3-million-from-national-cancer-institute-to-develop-personalized-medicine-tests/</link>
		<comments>http://www.2020gene.com/october-8-2010-2020-genesystems-awarded-3-million-from-national-cancer-institute-to-develop-personalized-medicine-tests/#comments</comments>
		<pubDate>Mon, 08 Nov 2010 20:17:53 +0000</pubDate>
		<dc:creator>bcohen</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.2020gene.com/?p=1086</guid>
		<description><![CDATA[Diagnostics using patented L-IHC technology will help oncologists select targeted treatments for kidney, breast, and other solid tumors by simultaneously profiling entire mTOR signaling pathway. ROCKVILLE, MD (Oct. 11, 2010) –20/20 GeneSystems, Inc. (&#8220;20/20&#8243; ) announced today that the company has been awarded nearly $3 million in grants from the National Cancer Institute’s (NCI) Small [...]]]></description>
		<wfw:commentRss>http://www.2020gene.com/october-8-2010-2020-genesystems-awarded-3-million-from-national-cancer-institute-to-develop-personalized-medicine-tests/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>September 14, 2010     New Multiplex Tissue Biomarker Technology Launched to Advance Personalized Medicine</title>
		<link>http://www.2020gene.com/september-14-2010-new-multiplex-tissue-biomarker-technology-launched-to-advance-personalized-medicine/</link>
		<comments>http://www.2020gene.com/september-14-2010-new-multiplex-tissue-biomarker-technology-launched-to-advance-personalized-medicine/#comments</comments>
		<pubDate>Tue, 14 Sep 2010 16:12:25 +0000</pubDate>
		<dc:creator>bcohen</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.2020gene.com/?p=1080</guid>
		<description><![CDATA[20/20 GeneSystems’ Layered IHC permits for the first time 10+ biomarkers within intact tissue sections to be analyzed simultaneously. The technology offers a superior platform for companion diagnostics to molecularly targeted therapeutics. ARLINGTON, Va.&#8211;(BUSINESS WIRE)&#8211;20/20 GeneSystems, Inc. (“20/20” ) announced today at ADAPT 2010, an industry meeting focusing on advancing personalized medicine, the commercial launch [...]]]></description>
		<wfw:commentRss>http://www.2020gene.com/september-14-2010-new-multiplex-tissue-biomarker-technology-launched-to-advance-personalized-medicine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>20/20 launches its new L-IHC lab services July 1, 2010 using its proprietary multilayer IHC platform for the development of new companion diagnostics.</title>
		<link>http://www.2020gene.com/761/</link>
		<comments>http://www.2020gene.com/761/#comments</comments>
		<pubDate>Mon, 28 Jun 2010 18:19:22 +0000</pubDate>
		<dc:creator>bcohen</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.2020gene.com/?p=761</guid>
		<description><![CDATA[20/20 launches its new L-IHC lab services.  Beginning July 1, 20/20 will begin using its proprietary multilayer IHC platform for the development of new companion diagnostics.  Services will be preformed in 20/20&#8242;s Rockville MD laboratory under the direction of  Michael Leibowitz Phd.  New customized studies will be developed and run for leading cancer research centers [...]]]></description>
		<wfw:commentRss>http://www.2020gene.com/761/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Smiths Detection to Distribute Emergency Response Biological Screening Kits Globally</title>
		<link>http://www.2020gene.com/smiths-detection-to-distribute-emergency-response-biological-screening-kits-globally/</link>
		<comments>http://www.2020gene.com/smiths-detection-to-distribute-emergency-response-biological-screening-kits-globally/#comments</comments>
		<pubDate>Sun, 17 Jan 2010 23:46:58 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://beta.2020gene.com/?p=189</guid>
		<description><![CDATA[Partnership Leverages Smiths Detection’s Global Security Expertise and 20/20 BioResponse’s BioCheck® Technology to Enhance Edgewood, MD, 17 February 2010 &#8211; Smiths Detection today announces a world-wide distribution agreement with 20/20 BioResponse for its BioCheck powder screening test kits. The partnership adds a low-cost, highly-effective biological threat assessment tool to strengthen Smiths Detection’s portfolio of proven [...]]]></description>
		<wfw:commentRss>http://www.2020gene.com/smiths-detection-to-distribute-emergency-response-biological-screening-kits-globally/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>20/20 GeneSystems Receives $650,000 Award to Develop Test to “Personalize” Breast Cancer Therapies</title>
		<link>http://www.2020gene.com/2020-genesystems-receives-650000-award-to-develop-test-to-%e2%80%9cpersonalize%e2%80%9d-breast-cancer-therapies/</link>
		<comments>http://www.2020gene.com/2020-genesystems-receives-650000-award-to-develop-test-to-%e2%80%9cpersonalize%e2%80%9d-breast-cancer-therapies/#comments</comments>
		<pubDate>Tue, 29 Sep 2009 23:49:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://beta.2020gene.com/?p=192</guid>
		<description><![CDATA[ROCKVILLE, MD (September 29, 2008)&#8211;20/20 GeneSystems, Inc. (“20/20”) announced today that the U.S. National Cancer Institute (NCI) has awarded the company a grant of $650,000 under its Small Business Innovative Research (SBIR) program to utilize its patented tumor profiling technology to create new tests for selecting treatments for breast cancer. Despite advances in the early [...]]]></description>
		<wfw:commentRss>http://www.2020gene.com/2020-genesystems-receives-650000-award-to-develop-test-to-%e2%80%9cpersonalize%e2%80%9d-breast-cancer-therapies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

